Glycoprotein IIb/IIIa inhibitors in patients with renal insufficiency undergoing percutaneous coronary intervention

Cardiology in Review

Volumn 16, Issue 4, 2008, Pages 213-218

  Anderson, Joe R ^a   Riding, Dan ^b  

^a UNIVERSITY OF NEW MEXICO   (United States)

^b Salt Lake City Veterans Administration   (United States)

Author keywords

Bleeding; Glycoprotein iib iiia inhibitors; Percutaneous coronary intervention; Renal insufficiency

Indexed keywords

ABCIXIMAB; EPTIFIBATIDE; HEPARIN; HIRULOG; LOW MOLECULAR WEIGHT HEPARIN; TIROFIBAN; ANTITHROMBOCYTIC AGENT; DRUG DERIVATIVE; FIBRINOGEN RECEPTOR; IMMUNOGLOBULIN F(AB) FRAGMENT; MONOCLONAL ANTIBODY; PEPTIDE; TYROSINE;

BLEEDING; BLOOD TRANSFUSION; BRAIN HEMORRHAGE; CEREBROVASCULAR BLEEDING; CLINICAL TRIAL; DOSE RESPONSE; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG SAFETY; GASTROINTESTINAL HEMORRHAGE; HUMAN; KIDNEY FAILURE; KIDNEY FUNCTION; PERCUTANEOUS CORONARY INTERVENTION; RETROPERITONEAL HEMORRHAGE; REVIEW; RISK FACTOR; THROMBOCYTOPENIA; ACUTE CORONARY SYNDROME; DRUG ANTAGONISM; DRUG COMBINATION; EVIDENCE BASED MEDICINE; PRACTICE GUIDELINE; TRANSLUMINAL CORONARY ANGIOPLASTY; TREATMENT OUTCOME;

ACUTE CORONARY SYNDROME; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ANTIBODIES, MONOCLONAL; DRUG THERAPY, COMBINATION; EVIDENCE-BASED MEDICINE; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; PEPTIDES; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; PRACTICE GUIDELINES AS TOPIC; RENAL INSUFFICIENCY; TREATMENT OUTCOME; TYROSINE;

EID: 49149114545     PISSN: 10615377     EISSN: None     Source Type: Journal    
DOI: 10.1097/CRD.0b013e31817a7de9     Document Type: Review

References (31)

1. DiPiro JT, Talbert RL, Yee GC, et al. Pharmacotherapy a Pathophysiologic Approach. 6th ed. New York, NY: McGraw-Hill; 2005:305-308.
2. Boersma E, Harrington RA, Moliterno DJ, et al. Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: a meta-analysis of all major randomised clinical trials. Lancet. 2002;359:189-198.
3. Smith SC Jr, Feldman TE, Hirshfeld JW Jr, et al. ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention-summary article: a report of the American college of cardiology/American heart association task force on practice guidelines (ACC/AHA/SCAI Writing Committee to Update the 2001 Guidelines for Percutaneous Coronary Intervention). Circulation. 2006;113:156-175.
4. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. National Kidney Foundation. Am J Kidney Dis. 2002;39 (2 Suppl 1): S1-S266.
5. Al Suwaidi J, Redden DN, Williams K, et al. Prognostic implications of abnormalities in renal function in patients with acute coronary syndromes. Circulation. 2002;106:974-980.
6. Freeman RV, Mehta RH, Al Badr W, et al. Influence of concurrent renal dysfunction on outcomes of patients with acute coronary syndromes and implications of the use of glycoprotein IIb/IIIa inhibitors. J Am Coll Cardiol. 2003;41:718-724.
7. Reddan DN, Szczech LA, Tuttle RH, et al. Chronic kidney disease, mortality, and treatment strategies among patients with clinically significant coronary artery disease. J Am Soc Nephrol. 2003;14:2373-2380.
8. Best PJ, Lennon R, Ting HH, et al. The impact of renal insufficiency on clinical outcomes in patients undergoing percutaneous coronary interventions. J Am Coll Cardiol. 2002;39:1113-1119.
9. Coca SG, Krumholz HM, Garg AX, et al. Underrepresentation of renal disease in randomized controlled trials of cardiovascular disease. JAMA. 2006;296:1377-1384.
10. Kidney Disease Outcomes Quality Initiative (K/DOQI) Workgroup. K/DOQI clinical practice guidelines for cardiovascular disease in dialysis patients. Am J Kid Dis. 2005;45 (4 Suppl 3): S1-S153.
11. Sadeghi M, Stone GW, Grines CL, et al. Impact of renal insufficiency in patients undergoing primary angioplasty for acute myocardial infarction. Circulation. 2003;108:2769-2775.
12. Manoukian SV, Feit F, Mehran R, et al. Impact of major bleeding on 30-day mortality and clinical outcomes in patients with acute coronary syndromes: an analysis from the ACUITY trial. J Am Coll Cardiol. 2007;49:1362-1368.
13. Eikelboom JW, Mehta SR, Anand SS, et al. Adverse impact of bleeding on prognosis in patients with acute coronary syndromes. Circulation. 2006;114:774-782.
14. Lim MJ, Eagle KA, Gore JM, et al. Treating patients with acute coronary syndromes with aggressive antiplatelet therapy (from the Global Registry of Acute Coronary Events). Am J Cardiol. 2005;96:917-921.
15. Aggrastat (Tirofiban) Solution for Infusion [Product Monograph]. Haarlem: Merck Sharp and Dohme B. V.; 2003.
16. Schering Corporation. Integrilin (Eptifibatide) Injection for Intravenous Administration [Product Monograph]. New Jersey: Schering Corporation; 2005.
17. Eli Lilly and Company. ReoPro (Abciximab) for Intravenous Administration [Product Monograph]. Indianapolis, IN: Eli Lilly and Company; 2005.
18. Frilling B, Zahn B, Mark B, et al. Comparison of efficacy and complication rates after percutaneous coronary interventions in patients with and without renal insufficiency treated with abciximab. Am J Cardiol. 2002;89:450-452.
19. Jeremias A, Bhatt DL, Chew DP, et al. Safety of abciximab during percutaneous coronary intervention in patients with chronic renal insufficiency. Am J Cardiol. 2002;89:1209-1211.
20. Best PJ, Lennon R, Gersh BJ, et al. Safety of abciximab in patients with chronic renal insufficiency who are undergoing percutaneous coronary interventions. Am Heart J. 2003;146:345-350.
21. Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) Study Investigators. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. N Engl J Med. 1998;338:1488-1497.
22. Januzzi JL, Snapinn SM, DiBattiste PM, et al. Benefits and safety of tirofiban among acute coronary syndrome patients with mild to moderate renal insufficiency. Circulation. 2002;105:2361-2366.
23. Chesebro JH, Knatterud G, Roberts R, et al. Thrombolysis in Myocardial Infarction (TIMI) trial, phase I: a comparison between intravenous tissue plasminogen activator and intravenous streptokinase: clinical findings through hospital discharge. Circulation. 1987;76:142-154.
24. The TARGET Investigators. Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization. N Engl J Med. 2001;344:1888-1894.
25. Berger PB, Best PJ, Topol EJ, et al. The relation of renal function to ischemic and bleeding outcomes with 2 different glycoprotein IIb/IIIa inhibitors: the do tirofiban and ReoPro give similar efficacy outcome (TARGET) trial. Am Heart J. 2005;149:869-875.
26. The ESPRIT Investigators. Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT): a randomized, placebocontrolled trial. Lancet. 2000;356:2037-2044.
27. The ESPRIT Investigators. Platelet glycoprotein IIb/IIIa integrin blockade with eptifibatide in coronary stent intervention. JAMA. 2001;285: 2468-2473.
28. Reddan DN, O'Shea JC, Sarembock IJ, et al. Treatment effects of eptifibatide in planned coronary stent implantation in patients with chronic kidney disease (ESPRIT Trial). Am J Cardiol. 2003;91:17-21.
29. Kirtane AJ, Piazza G, Murphy SA, et al. Correlates of bleeding events among moderate-to high risk patients undergoing percutaneous coronary intervention and treated with eptifibatide: observations from the PROTECT-TIMI-30 Trial. J Am Coll Cardiol. 2006;47:2374-2379.
30. Gibson CM, Morrow DA, Murphy SA, et al. A randomized trial to evaluate the relative protection against post-percutaneous coronary intervention microvascular dysfunction, ischemia, and inflammation among antiplatelet and antithrombotic agents: the PROTECT-TIMI-30 Trial. J Am Coll Cardiol. 2006;47:2364-2373.
31. Alexander KP, Chen AY, Roe MT, et al. Excess dosing of antiplatelet and antithrombin agents in the treatment of non-ST-segment elevation acute coronary syndromes. JAMA. 2005;294:3108-3116.